DSE 9912

Drug Profile

DSE 9912

Alternative Names: SEK 3001

Latest Information Update: 08 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sekisui
  • Developer Dainippon Sumitomo Pharma; Sekisui
  • Class Tocopherols; Vitamins
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Atopic dermatitis

Most Recent Events

  • 08 Feb 2008 Discontinued - Phase-I for Atopic dermatitis in Japan (Topical)
  • 01 Oct 2005 Sumitomo Pharmaceuticals has merged with Dainippon Pharmaceutical to form Dainippon Sumitomo Pharma
  • 28 May 2001 SEK 3001 is now called DSE 9912
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top